Prospect Hill Management LLC Takes Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• Prospect Hill Management initiated a 3,000-share position in Thermo Fisher Scientific during the second quarter, valued at approximately $1.5 million. Institutional investors and hedge funds collectively own 89.23% of the company.
• Analysts maintain a generally positive view, with a consensus rating of “Moderate Buy” and an average price target of $619.41, despite some recent target-price reductions.
• Thermo Fisher exceeded quarterly expectations, reporting $6.03 in EPS and $11.99 billion in revenue, while revenue grew 10.5% year over year. The company also declared a quarterly dividend of $0.47 per share, yielding approximately 0.3%.

Prospect Hill Management LLC purchased a new position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 3,000 shares of the medical research company's stock, valued at approximately $1,504,000. Thermo Fisher Scientific makes up about 0.6% of Prospect Hill Management LLC's investment portfolio, making the stock its 11th largest holding.

Several other institutional investors and hedge funds have also recently bought and sold shares of TMO. Salomon & Ludwin LLC lifted its holdings in Thermo Fisher Scientific by 1.6% during the 4th quarter. Salomon & Ludwin LLC now owns 1,095 shares of the medical research company's stock worth $669,000 after buying an additional 17 shares during the last quarter. Elyxium Wealth LLC raised its position in shares of Thermo Fisher Scientific by 1.9% during the 4th quarter. Elyxium Wealth LLC now owns 1,058 shares of the medical research company's stock valued at $613,000 after acquiring an additional 20 shares in the last quarter. Revolve Wealth Partners LLC lifted its stake in Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after purchasing an additional 20 shares during the last quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. boosted its holdings in Thermo Fisher Scientific by 0.7% in the third quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. now owns 2,960 shares of the medical research company's stock worth $1,436,000 after purchasing an additional 20 shares during the period. Finally, Confluence Wealth Services Inc. increased its stake in Thermo Fisher Scientific by 0.5% during the fourth quarter. Confluence Wealth Services Inc. now owns 4,292 shares of the medical research company's stock valued at $2,487,000 after purchasing an additional 22 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. KeyCorp restated an "overweight" rating on shares of Thermo Fisher Scientific in a research report on Tuesday, May 26th. Robert W. Baird cut their target price on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an "outperform" rating on the stock in a report on Friday, April 24th. Wells Fargo & Company decreased their target price on Thermo Fisher Scientific from $675.00 to $615.00 and set an "overweight" rating for the company in a research note on Friday, May 8th. Weiss Ratings raised Thermo Fisher Scientific from a "hold (c-)" rating to a "hold (c)" rating in a report on Tuesday, July 14th. Finally, Wall Street Zen raised Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Saturday, August 1st. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $619.41.

Insider Activity

In related news, VP Lisa P. Britt sold 5,850 shares of Thermo Fisher Scientific stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $580.00, for a total transaction of $3,393,000.00. Following the sale, the vice president directly owned 14,784 shares in the company, valued at $8,574,720. The trade was a 28.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Joseph R. Holmes sold 420 shares of the company's stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $584.81, for a total transaction of $245,620.20. Following the completion of the sale, the chief accounting officer directly owned 2,966 shares of the company's stock, valued at $1,734,546.46. The trade was a 12.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 52,053 shares of company stock worth $30,643,589 over the last ninety days. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Stock Down 0.3%

TMO stock opened at $586.62 on Tuesday. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The firm's 50-day simple moving average is $531.72 and its 200 day simple moving average is $508.48. The stock has a market cap of $216.90 billion, a PE ratio of 31.56, a price-to-earnings-growth ratio of 2.39 and a beta of 0.84. Thermo Fisher Scientific Inc. has a fifty-two week low of $435.27 and a fifty-two week high of $643.99.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm had revenue of $11.99 billion during the quarter, compared to analysts' expectations of $11.71 billion. During the same quarter in the prior year, the firm earned $4.28 EPS. Thermo Fisher Scientific's quarterly revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be given a $0.47 dividend. This represents a $1.88 annualized dividend and a yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 10.11%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source